Journal of Radiation Research最新文献

Radiotherapy for human T-cell leukemia virus type 1-associated adult T-cell leukemia/lymphoma. 人类t细胞白血病病毒1型相关成人t细胞白血病/淋巴瘤的放疗

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-12 DOI: 10.1093/jrr/rraf036

Kohei Tokuyama, Takayoshi Itaya, Ayaka Hara, Motoko Tanabe, Shoko Takata, Takashige Kiyota, Tomoko Yamate, Yutaka Hatano, Masao Ogata, Kuniko Takano, Yoshiki Asayama

{"title":"Radiotherapy for human T-cell leukemia virus type 1-associated adult T-cell leukemia/lymphoma.","authors":"Kohei Tokuyama, Takayoshi Itaya, Ayaka Hara, Motoko Tanabe, Shoko Takata, Takashige Kiyota, Tomoko Yamate, Yutaka Hatano, Masao Ogata, Kuniko Takano, Yoshiki Asayama","doi":"10.1093/jrr/rraf036","DOIUrl":"https://doi.org/10.1093/jrr/rraf036","url":null,"abstract":"Adult T-cell lymphoma/leukemia (ATL) is an aggressively malignant peripheral T-cell neoplasm. Only a few studies have reported the use of radiotherapy (RT) for ATL. Therefore, the aim of this study was to clarify the efficacy of RT for ATL. We retrospectively reviewed 90 courses of RT administered to 19 consecutive ATL patients between 2008 and 2023. The subtypes included lymphoma (n = 8), acute (n = 7), smoldering (n = 3) and unknown (n = 1). Ninety lesions (cutaneous = 72, extranodal = 10, nodal = 8) were treated at a mean dose of 39.1 Gy/3.2 Gy (range, 24-60 Gy). Administration of RT for ATL lesions resulted in a combined complete response and partial response rate of 92%. At a mean of 47.5 months of follow-up (range, 0-102 months), local recurrence was not observed in 98.9% of the courses. A treatment response in terms of clinical symptoms was observed in 92% of the courses. The median survival time was 918 days. No acute grade ≥3 toxicity or any late toxicity was noted. In conclusion, RT was confirmed to be effective and safe for the treatment of local ATL lesions.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model. CCR5拮抗剂在小鼠模型中增强肝癌的放射敏感性。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-07-12 DOI: 10.1093/jrr/rraf035

Junying Chen, Qiaojing Lin, Ruilong Lan, Jiandong Wu, Zeng Wang, Ruiqing Chen, Weikang Huang, Danqing Liu, Yunhua Yang, Jinsheng Hong

{"title":"A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model.","authors":"Junying Chen, Qiaojing Lin, Ruilong Lan, Jiandong Wu, Zeng Wang, Ruiqing Chen, Weikang Huang, Danqing Liu, Yunhua Yang, Jinsheng Hong","doi":"10.1093/jrr/rraf035","DOIUrl":"https://doi.org/10.1093/jrr/rraf035","url":null,"abstract":"Conventional fractionated radiotherapy (CFRT) for hepatocellular carcinoma (HCC) is limited by intrinsic radioresistance. In this study, we investigated the radiosensitizing potential of maraviroc, a chemokine receptor 5 (CCR5) antagonist, and its mechanistic basis in HCC. A murine HCC model was established by subcutaneous implantation of H22 cells into the hind limbs of mice. Tumor-bearing mice received CFRT with or without maraviroc, and tumor growth kinetics were evaluated. Systemic levels of myeloid-derived suppressor cells (MDSCs) in peripheral blood and plasma chemokine ligand 5 (CCL5) were longitudinally monitored post-irradiation. In vitro mechanistic studies utilized maraviroc combined with conditioned media from 2 Gy-irradiated H22 cells to dissect its radiosensitizing effects. H22 cell viability, proliferation and migration were assessed following irradiation with or without maraviroc. Flow cytometry was employed to quantify polymorphonuclear MDSC (PMN-MDSC) proliferation, differentiation and immunosuppressive capacity via T-cell proliferation assays. Compared to monotherapy with either CFRT or maraviroc alone, maraviroc combined with CFRT significantly inhibited HCC growth in the mouse model. In vitro, maraviroc did not directly enhance irradiation-induced H22 cell death or suppress proliferation but reversed PMN-MDSC-mediated immunosuppression by attenuating PMN-MDSC migration and abrogating PMN-MDSC suppression of T-cell proliferation. Maraviroc combined with CFRT significantly inhibited the differentiation of bone marrow cells into PMN-MDSCs. In conclusion, the synergistic application of CCR5 antagonist with CFRT significantly enhanced radiosensitivity in HCC, primarily through suppression of PMN-MDSCs differentiation and migration, coupled with blockade of their T-cell proliferation inhibitory functions.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine. 131i -间碘苄基胍内靶向放疗对人源癌和正常细胞HMGB1释放的影响

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-30 DOI: 10.1093/jrr/rraf034

Kakeru Sato, Ririka Handa, Jianwei Yao, Yuka Hirayama, Yuna Hamada, Jundai Yamagata, Taiga Watanabe, Asuka Mizutani, Hiroshi Wakabayashi, Masato Kobayashi, Ryuichi Nishii, Keiichi Kawai

{"title":"Release of HMGB1 from human-derived cancer and normal cells by internal targeted radiotherapy with 131I-meta-iodobenzylguanidine.","authors":"Kakeru Sato, Ririka Handa, Jianwei Yao, Yuka Hirayama, Yuna Hamada, Jundai Yamagata, Taiga Watanabe, Asuka Mizutani, Hiroshi Wakabayashi, Masato Kobayashi, Ryuichi Nishii, Keiichi Kawai","doi":"10.1093/jrr/rraf034","DOIUrl":"https://doi.org/10.1093/jrr/rraf034","url":null,"abstract":"The rare abscopal effect in radiotherapy is thought to result from immune-activating damage-associated molecular patterns, such as high mobility group box-1 protein (HMGB1), released from cancer cells. While external irradiation of cancer cells increases HMGB1 release, it remains unclear whether internal radiotherapy with 131I-meta-iodobenzylguanidine (131I-MIBG) induces similar effects. This study aimed to determine if HMGB1 is released from human-derived cancer and normal cells after 131I-MIBG administration. The number of cells, extracellular lactate dehydrogenase (LDH) and HMGB1 were measured in H441 and human keratinocyte cell line (HaCaT) at 1 day after 2- and 10-Gy X-ray irradiation. Accumulations of 131I-MIBG in SH-SY5Y and HaCaT were measured at 60 min after 131I-MIBG (0.37, 1.85 and 3.7 MBq/well) administration. The number of cells, extracellular LDH and HMGB1 were measured at 1 day after 131I-MIBG treatment. Results: The total number of cells decreased in both H441 and HaCaT at 1 day after 10-Gy X-ray irradiation. Extracellular LDH and HMGB1 from H441 after 10-Gy X-ray irradiation were significantly increased, while no increase was observed in HaCaT after 2- and 10-Gy X-ray irradiation. After 1.85 MBq (~4-Gy by converting of PHITS simulation) and 3.7 MBq 131I-MIBG (8-Gy) administrations, the total number of cells decreased in both SH-SY5Y and HaCaT at 1 day after 131I-MIBG administration. Extracellular LDH and HMGB1 were both significantly increased in SH-SY5Y, but only extracellular LDH was significantly increased in HaCaT. HMGB1 was released from neuroblastoma cells but not from normal cells after 131I-MIBG administration. A combination of 131I-MIBG and immunotherapy may be feasible.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a headgear-based eye protection device for physicians performing fluoroscopy-guided bronchoscopy. 开发一种基于头套的护眼装置，用于医生进行透视引导下的支气管镜检查。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-18 DOI: 10.1093/jrr/rraf031

Masaki Fujisawa, Yoshihiro Haga, Saki Takahira, Masahiro Sota, Toshiki Kato, Mitsuya Abe, Yuji Kaga, Yohei Inaba, Masatoshi Suzuki, Koichi Chida

{"title":"Development of a headgear-based eye protection device for physicians performing fluoroscopy-guided bronchoscopy.","authors":"Masaki Fujisawa, Yoshihiro Haga, Saki Takahira, Masahiro Sota, Toshiki Kato, Mitsuya Abe, Yuji Kaga, Yohei Inaba, Masatoshi Suzuki, Koichi Chida","doi":"10.1093/jrr/rraf031","DOIUrl":"https://doi.org/10.1093/jrr/rraf031","url":null,"abstract":"Fluoroscopy-guided bronchoscopy is an essential tool for diagnosing and treating lung diseases, particularly lung cancer. However, prolonged fluoroscopic exposure raises concerns regarding radiation-induced lens injuries in physicians, such as radiation cataracts. In response to the International Commission on Radiological Protection lowering the occupational lens dose limit to an average of 20 mSv/year over 5 years, there is an increasing need for effective lens protection during such procedures. This study has aimed to develop a novel lens protection device specifically designed for bronchoscopy physicians and evaluate its protective performance through a phantom study. The device consisted of a 0.175 mm lead (Pb) sheet positioned on the left side of the physician's head, secured with headgear to improve stability and comfort during prolonged use. A phantom study was conducted using a trunk phantom to simulate a patient and a head phantom to simulate a physician. The scattered radiation doses were measured at 15 locations on the phantom head using a radiophotoluminescence glass dosimeter, both with and without a protective device. The device demonstrated a protective effect of more than 80% for the left eye across all tested angles, whereas the right eye showed protection ranging from approximately 40% to 75% depending on the angle. This novel lens protection device has the potential to significantly reduce scattered radiation to the left eye while minimizing vision obstruction and discomfort. This offers a practical solution for radiation protection during bronchoscopy and may be applicable to other interventional procedures requiring fluoroscopic guidance.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma. 旋转龙门碳离子放射治疗脉络膜恶性黑色素瘤的前瞻性研究。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-10 DOI: 10.1093/jrr/rraf030

Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota

{"title":"Prospective study of a rotating gantry with scanning beams of carbon-ion radiotherapy for choroidal malignant melanoma.","authors":"Masaru Wakatsuki, Hirokazu Makishima, Shuri Aoki, Nao Kobayashi, Hiroshi Tsuji, Hitoshi Ishikawa, Shigeru Yamada, Atsushi Mizota","doi":"10.1093/jrr/rraf030","DOIUrl":"https://doi.org/10.1093/jrr/rraf030","url":null,"abstract":"To evaluate the safety of a rotating gantry with scanning beams of carbon-ion radiotherapy (C-ion RT) for choroidal malignant melanoma. A prospective study of C-ion RT using a rotating gantry with scanning beams for choroidal malignant melanoma was initiated at the National Institute for Quantum Science and Technology, QST Hospital in March 2018. The inclusion criteria were as follows: (i) clinically diagnosed ocular/choroidal malignant melanoma; (ii) tumor measurable by imaging tests; (iii) score of 0-2 on the Eastern Cooperative Oncology Group Performance Status scale and (iv) ability to provide consent for treatment. All patients received 68 Gy in four fractions of C-ion RT by a rotating gantry with scanning beams. Between April 2018 and July 2019, 21 patients were enrolled and underwent C-ion RT as planned. All 21 patients completed the treatment schedule and the 3-year follow-up period. The median duration of follow-up was 43 months (range, 35.2-54.6 months). Regarding late normal tissue responses, three of the 21 patients developed grade 2 neovascular glaucoma; however, no other late grade ≥2 acute toxicities were observed. During the 3-year study period, all 21 patients survived with no local recurrence; none of the patients underwent enucleation. Three cases showed liver metastasis. The 3-year local control, overall survival and eye-retention rates were all 100%. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small. The results of this prospective study confirmed that the effectiveness and safety of this method are equivalent to those of conventional passive irradiation methods, although the number of cases was small.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relative risk of cardiac mortality and dosimetric comparison among three-dimensional radiotherapy, volume-modulated arc therapy and proton beam in vertebral-body reduced-dose craniospinal irradiation. 三维放疗、体积调节电弧治疗和质子束椎体-颅脊柱低剂量照射中心脏死亡率的相对风险和剂量学比较。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-10 DOI: 10.1093/jrr/rraf032

Chonnipa Nantavithya, Anussara Prayongrat, Sornjarod Oonsiri, Kanjana Shotelersuk

{"title":"Relative risk of cardiac mortality and dosimetric comparison among three-dimensional radiotherapy, volume-modulated arc therapy and proton beam in vertebral-body reduced-dose craniospinal irradiation.","authors":"Chonnipa Nantavithya, Anussara Prayongrat, Sornjarod Oonsiri, Kanjana Shotelersuk","doi":"10.1093/jrr/rraf032","DOIUrl":"https://doi.org/10.1093/jrr/rraf032","url":null,"abstract":"We aimed to compare dose to organs at risk (OARs) and the excess relative risk (ERR) of cardiac mortality among three-dimensional conformal radiotherapy (3D-CRT), volume modulated arc therapy (VMAT) and proton beam therapy (PBT) in craniospinal irradiation (CSI). CSI plans of 3D-CRT, VMAT and PBT were generated. Vertebral body reduced dose (VBR)-CSI according to the International Society of Paediatric Oncology recommendation was used for VMAT and PBT. We delineated two sets of target volumes, i.e. target volume (TV) 1 for brain and thecal sac and TV2 for the vertebral body. Two sets of CSI dose, 23.4 and 36 Gy, were prescribed for TV1, and VBR doses, 18.4 and 20 Gy, were prescribed for TV2. For 3D-CRT, we prescribed a dose only to cover TV1. For VMAT and PBT, 23.4/18.4Gy and 36/20 Gy in 13 and 20 fractions were optimized. To evaluate the ERR of cardiac mortality compared with the normal population, we incorporate the mean heart dose with the linear model. In a total of eight patients, 48 treatment plans were generated (24 plans for each dose set). PBT showed the lowest mean dose to all OARs, i.e. heart, lung, liver, kidney, esophagus, oral cavity, thyroid and vertebral body. PBT showed significantly less ERR of cardiac mortality compared with 3D-CRT and VMAT for both 23.4 and 36 Gy prescriptions. With VBR-CSI, PBT reduced the mean dose to all OARs and significantly reduced the ERR of cardiac mortality compared with 3D-CRT and VMAT. The advantage of PBT was manifest, especially with high-dose CSI.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences. 立体定向放射治疗肾细胞癌：少量初步临床经验。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf028

Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira

{"title":"Stereotactic body radiation therapy for renal cell carcinoma: a small number of initial clinical experiences.","authors":"Takahiro Aoyama, Yutaro Koide, Hidetoshi Shimizu, Tomoki Kitagawa, Tohru Iwata, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira","doi":"10.1093/jrr/rraf028","DOIUrl":"https://doi.org/10.1093/jrr/rraf028","url":null,"abstract":"Stereotactic body radiation therapy (SBRT) has emerged as a promising and minimally invasive treatment option for patients with renal cell carcinoma (RCC). This study presents our initial clinical experiences with treatments following our center's protocol, which was formulated based on both national and international evidence. Six patients who had undergone renal SBRT at our center from January 2021 to December 2023 were included. Treatment planning used computed tomography (CT) and magnetic resonance imaging, with respiratory management conducted through breath-hold or free-breathing techniques. The prescribed dose was primarily 48 Gy in three fractions, with increased fractionations when dose constraints were challenging to achieve. Dose constraints were met for all patients, and treatment planning adhered to protocol guidelines. After the confirmation of cone-beam CT (CBCT) images by physicians, radiation was delivered. Five out of six patients completed the planned treatment, whereas one discontinued the treatment midway (the causal relationship to radiation therapy was unclear). Dose-volume histogram analysis revealed that doses to organs at risk depended on the position and size of the planning target volume but remained within acceptable limits for all cases. The intrafractional patient motion was 2.7 mm, as calculated from the pre- and post-CBCT images, confirming the appropriateness of a 3-mm setup margin. Although this study provides initial insights, further clinical trials are warranted to establish standardized protocols and optimize treatment strategies for RCC. In the future, it is also necessary to generate evidence that is tailored to the current situation in Japan.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning. 食管癌放疗治疗计划：JASTRO指南2024放疗治疗计划。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf029

Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno

{"title":"Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.","authors":"Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno","doi":"10.1093/jrr/rraf029","DOIUrl":"https://doi.org/10.1093/jrr/rraf029","url":null,"abstract":"The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The glymphatic system in oncology: from the perspective of a radiation oncologist. 肿瘤学中的淋巴系统：从放射肿瘤学家的角度。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-06-03 DOI: 10.1093/jrr/rraf027

Kentaro Nishioka, Mariko Kawamura, Mami Iima, Daiju Ueda, Rintaro Ito, Tsukasa Saida, Ryo Kurokawa, Koji Takumi, Akihiko Sakata, Satoru Ide, Maya Honda, Masahiro Yanagawa, Shunsuke Sugawara, Seitaro Oda, Tadashi Watabe, Keitaro Sofue, Kenji Hirata, Shinji Naganawa

{"title":"The glymphatic system in oncology: from the perspective of a radiation oncologist.","authors":"Kentaro Nishioka, Mariko Kawamura, Mami Iima, Daiju Ueda, Rintaro Ito, Tsukasa Saida, Ryo Kurokawa, Koji Takumi, Akihiko Sakata, Satoru Ide, Maya Honda, Masahiro Yanagawa, Shunsuke Sugawara, Seitaro Oda, Tadashi Watabe, Keitaro Sofue, Kenji Hirata, Shinji Naganawa","doi":"10.1093/jrr/rraf027","DOIUrl":"https://doi.org/10.1093/jrr/rraf027","url":null,"abstract":"The brain and spinal cord, which constitute the central nervous system, were historically considered immune-privileged sites, as it was believed they lacked an equivalent to the systemic lymphatic system. However, in 2013, a pathway facilitating the clearance of waste products through the brain parenchyma via the perivascular space was proposed, garnering attention as the 'glymphatic system'. Similar to the systemic lymphatic system, the glymphatic system plays a critical role in immune responses and has been implicated not only in Alzheimer's disease and inflammatory brain disorders but also in conditions such as hydrocephalus and glaucoma, which are associated with cerebrospinal fluid circulation impairments. Recent studies have suggested that dysfunction of the glymphatic system may promote the progression of brain tumors and reduce the efficacy of immune responses and pharmacological therapies targeting tumors. Radiotherapy is a major treatment option for brain tumors; however, while it can enhance immune responses against tumors, it may also suppress these responses at the same time. Additionally, cranial irradiation has been suggested to impair the function of the glymphatic system. This review provides an overview of the structure and functional evaluation methods of the glymphatic system, summarizes the effects of its dysfunction on brain tumor treatment, and explores recent findings on the impact of radiation therapy on glymphatic system functioning. Lastly, it also explores the potential for radiation therapy strategies that account for their effects on the glymphatic system.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems. 临床使用点扫描质子-碳离子同步加速器系统时治疗师的职业辐射暴露。

IF 1.9 4区医学

Journal of Radiation Research Pub Date : 2025-05-30 DOI: 10.1093/jrr/rraf023

Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang

{"title":"Occupational radiation exposure of therapists in clinical use of spot scanning proton-carbon ion synchrotron systems.","authors":"Zhulei Liu, Dan You, Dan Zhou, Ruirui Bu, Yao Li, Xiaowa Wang","doi":"10.1093/jrr/rraf023","DOIUrl":"https://doi.org/10.1093/jrr/rraf023","url":null,"abstract":"This study addresses the escalating radiation safety concerns among medical professionals due to the rising application of proton and carbon ion radiotherapy. It evaluates the occupational radiation exposure faced by therapists when utilizing the Siemens IONTRIS Proton-Carbon Ion System. Through random sampling of 80 patients treated between January and June 2024, we recorded particle types and counts and measured dose rates using a photon/neutron radiation dose meter. Notably, 1 min post-treatment, the dose rate peaked at 16.00 μSv/h near the tumor's skin surface, showing a significant correlation with particle count. The therapist's standing position and the surfaces of the range shifter and ripple filter registered average dose rates of 1.25 μSv/h and 3.63 μSv/h, 0.33 μSv/h, respectively. Other points averaged 0.08 μSv/h, with no neutron detection. The study concludes that the annual average occupational exposure for therapists, at ~300 μSv, is significantly below the International Commission on Radiological Protection's recommended dose equivalent limit, confirming the safety of the Siemens IONTRIS device in clinical settings.","PeriodicalId":16922,"journal":{"name":"Journal of Radiation Research","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0